{
    "clinical_study": {
        "@rank": "153115", 
        "acronym": "ACCORD", 
        "arm_group": {
            "arm_group_label": "Aerosure", 
            "arm_group_type": "Experimental", 
            "description": "All subjects receive an active device, sham device (disabled) and no device in a randomised sequence."
        }, 
        "brief_summary": {
            "textblock": "To investigate whether high frequency airflow oscillation (HFAO), delivered using Aerosure,\n      increases six minute walk distance (6MWD) and reduces exertional breathlessness in patients\n      with severe chronic obstructive pulmonary disease (COPD)."
        }, 
        "brief_title": "Aerosure and Six Minute Walk Distance in Severe COPD", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": [
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Stable severe COPD (FEV1 < 50% predicted)\n\n          -  Modified MRC dyspnoea score 2 or greater\n\n          -  At least 10 pack year smoking history\n\n          -  Able to mobilise independently\n\n        Exclusion Criteria:\n\n          -  Contraindications to spirometry [1]\n\n          -  Contraindications to clinical exercise testing [2]\n\n          -  Contraindications to HFAO (see section A.6.3b))\n\n          -  Resting SpO2>88% on air or on patient's usual oxygen prescription\n\n          -  Systolic arterial blood pressure (ABP) >200mmHg, diastolic ABP >100 mmHg\n\n               1. Cooper, B.G., An update on contraindications for lung function testing. Thorax,\n                  2010.\n\n               2. ATS/ACCP Statement on Cardiopulmonary Exercise Testing. Am. J. Respir. Crit.\n                  Care Med., 2003. 167(2): p. 211-277."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007590", 
            "org_study_id": "13.LO.1124"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aerosure", 
                "intervention_name": "Aerosure", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Aerosure", 
                "intervention_name": "Sham", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "SE5 9RS"
                }, 
                "name": "King's College Hospital, Bessemer Road, Denmark Hill"
            }, 
            "investigator": {
                "last_name": "Gerrard Rafferty, PhD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "Does High-frequency Airflow Oscillation, Delivered Using Aerosure, Increase Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease?", 
        "other_outcome": {
            "measure": "Inspiratory capacity (IC)", 
            "safety_issue": "No", 
            "time_frame": "At end of 6 minute walk test"
        }, 
        "overall_contact": {
            "email": "gerrard.rafferty@kcl.ac.uk", 
            "last_name": "Gerrard Rafferty"
        }, 
        "overall_contact_backup": {
            "email": "charles.c.reilly@kcl.ac.uk", 
            "last_name": "Charles C Reilly"
        }, 
        "overall_official": {
            "affiliation": "King's College Hospital NHS Trust", 
            "last_name": "John Moxham, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: National Health Service", 
                "United Kingdom: National Institute for Health Research", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Six minute walk distance (6MWD)", 
            "safety_issue": "No", 
            "time_frame": "up to 6 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007590"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "end-6MWD Borg breathlessness", 
                "safety_issue": "No", 
                "time_frame": "after 6 minute walk test"
            }, 
            {
                "measure": "Arterial oxygen saturation (SpO2)", 
                "safety_issue": "No", 
                "time_frame": "At start of 6 minute walk test and after every 1 minute"
            }
        ], 
        "source": "Actegy Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Actegy Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}